It is known that HO-1 and its byproducts have strong anti-inflammatory effects and new lines of evidence suggest the therapeutic potential of targeting HO-1 in several diseases set in the wide context of inflammation, such as inflammatory arthritis [141], psoriasis [142], neuroinflammation [143], and inflammatory bowel disease [144,145]. Here, HMOX1 is linked to psoriasis.